EUVIMEDEUVIMED entdecken
Leitlinie

Australasian Society of Infectious Diseases updated guidelines for the management of Clostridioides difficile infection in adults and children in Australia and New Zealand

Anthony Longhitano iD, Christine Roder, Tim Blackmore, Anita Campbell, Meryta May, Eugene Athan

Internal Medicine Journal · 2025

DOI: 10.1111/imj.16638 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Anthony Longhitano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Barwon Health, Geelong, Victoria, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Clostridioides difficile, Clostridium Infections, Disease Management. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clostridioides difficile infection (CDI) is associated with significant morbidity and mortality within the Australian population. Treatment recommendations for CDI pose challenges at both community and hospital‐based levels due to the recurrent, refractory and potentially severe nature of the disease. Since the last published Australasian guidelines in 2016, new therapeutic options are available, prompting a necessary update to management recommendations. On behalf of the Australasian Society of Infectious Diseases, we present the updated guidelines for the management of CDI in adults and children exploring the changes to treatment recommendations – including the replacement of oral metronidazole with vancomycin for initial CDI and the emerging role for fidaxomicin and faecal‐microbiota transplant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsClostridioides difficileClostridium InfectionsDisease ManagementAdultChildHumansAustraliaFecal Microbiota TransplantationFidaxomicinMetronidazoleNew ZealandSocieties, MedicalVancomycin

Stichwörter der Autor:innen

faecal microbiota transplantfaecal‐microbiota transplantfidaxomicinmetronidazolevancomycin

Substanzen

Anti-Bacterial AgentsFidaxomicinMetronidazoleVancomycin

Autor:innen und Institutionen

  • Department of Infectious Diseases, Barwon Health, Geelong, Victoria, Australia.
  • Barwon Health, Barwon Southwest Public Health Unit, Geelong, Victoria, Australia.
  • Department of Microbiology, Wellington Southern Community Laboratories, Wellington, New Zealand.
  • Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia.
  • Department of Microbiology, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia.

ORCID-Profile: Anthony Longhitano

Zitieren

APA

Longhitano, A., Roder, C., Blackmore, T., Campbell, A., May, M., & Athan, E. (2025). Australasian Society of Infectious Diseases updated guidelines for the management of Clostridioides difficile infection in adults and children in Australia and New Zealand. Internal Medicine Journal. https://doi.org/10.1111/imj.16638

Vancouver

Longhitano A, Roder C, Blackmore T, Campbell A, May M, Athan E. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridioides difficile infection in adults and children in Australia and New Zealand. Internal Medicine Journal. 2025. doi:10.1111/imj.16638

BibTeX
@article{Longhitano2025,
  author = {Longhitano, Anthony and Roder, Christine and Blackmore, Tim and Campbell, Anita and May, Meryta and Athan, Eugene},
  title = {Australasian Society of Infectious Diseases updated guidelines for the management of Clostridioides difficile infection in adults and children in Australia and New Zealand},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.16638}
}
Kostenlos starten →